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Background/aim: The aims of this study were to observe the interhormonal relationship of serum leptin with serum estradiol and to
compare pre- and postmenopausal women for possible implications in breast carcinogenesis.
Materials and methods: This comparative case-control study encompasses 175 breast cancer patients and 175 age-, sex-, and BMImatched healthy controls. For comparison, the subjects were divided into pre- and postmenopausal groups according to their menstrual
history. Blood samples were analyzed for serum leptin and serum estradiol by the ELISA method.
Results: Higher mean values of serum estrogen and leptin were observed in breast cancer cases among both the pre- and postmenopausal
groups. While estimating the association of serum leptin with serum estradiol, a weak positive (r = 0.186) but statistically significant (P
= 0.022) correlation was found among the premenopausal subjects, while a moderate positive association (r = 0.556) was found among
the postmenopausal subjects, which had high statistical significance (P = 0.001). Furthermore, correlation coefficients (r) of the pre- and
postmenopausal groups were compared using Fisher r-to-z transformation and found to have a statistically significant difference (z =
4.03, P = 0.0001).
Conclusion: The findings of this study suggest the mitogenic effects of leptin on mammary tissue via augmenting peripheral estrogen
production more significantly among postmenopausal subjects. Thus, the therapeutic modulation of leptin may be a potential adjuvant
treatment for breast cancer patients with high levels of leptin along with high estrogen concentration as a consequence.
Key words: Breast cancer, leptin, estradiol, menopause

1. Introduction
Adipose tissue, which is an active endocrine organ, plays
an important role in carcinogenesis via releasing proteins
having endocrine functions like leptin, adiponectin,
interleukin-6, and tumor necrosis factor-α (1). In
addition to synthesis of adipocytokines, adipose tissue
also contains a set of enzymes that can metabolize and
produce steroid hormones (2). The extent of its importance
is indicated by the almost complete contribution of
estrogen in postmenopausal women and half of the
testosterone in premenopausal women by adipose tissue
alone. Steroidogenic enzymes that are expressed in
adipose tissue include hydroxysteroid dehydrogenases,
hydroxylases, reductase, glucuronosyltransferase, and,
importantly, aromatase, which convert androstenedione
and testosterone to estrone and estradiol, respectively (3).
* Correspondence: danish-haseen@duhs.edu.pk

Leptin, an adipocytokine, is a 16-kDa-peptide hormone.
It is mainly present in adipose tissue and blood, while its
receptors are abundant in peripheral tissues (4). Leptin has
been linked with various cancers including endometrial,
gastric, prostate, and breast cancers. Expression of leptin
and its receptors were found in normal mammary tissue
as well as breast cancer tissue; both leptin and its receptors
have been found to be elevated in cancer tissue when
compared with normal tissue (5). Circulating leptin
concentration is associated with the incidence of breast
carcinoma, and induces breast cancer carcinogenesis
and invasion. Leptin exerts its growth effect on breast
cancer cell lines through direct activation of multiple
signaling cascades (6); however, increased expression of
aromatase enzyme by leptin in the adipose tissue may
indirectly promote carcinogenesis by augmenting estrogen
biosynthesis (7).
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The growing evidence for leptin being involved in
cell growth and proliferation of breast cancer opens up
many arguments about its possible mechanisms. The aim
of the present study was to observe the concentrations of
serum leptin and serum estradiol among diagnosed breast
cancer patients and healthy controls. Furthermore, this
study presents a novel comparison of the interhormonal
relationship of serum leptin with serum estrogen between
pre- and postmenopausal subjects.
2. Materials and methods
This comparative case-control study was conducted by
collaboration between the Department of Surgery, Civil
Hospital, Karachi, and the Department of Biochemistry,
University of Karachi. A total of 175 newly diagnosed
breast cancer patients presenting to the Breast Clinic,
Civil Hospital, Karachi, were enrolled after their informed
consent was obtained, while 175 healthy controls not
having any disease were recruited from various screening
camps. For comparison, the subjects were divided into preand postmenopausal groups according to their menstrual
history.
Sample size was estimated by using the 36.4%
frequency of breast cancer reported in a study conducted
by Bhurgri et al. (8) in Karachi, Pakistan. Ethical approval
was acquired from the Research and Ethics Committee,
Board of Advanced Studies and Research, University of
Karachi, vide letter no: BASR – 0716 / Sc. Those subjects
who had received any treatment for breast cancer,
including breast surgery, chemotherapy, or radiotherapy,
were excluded from the study. Subjects who were on
hormone replacement therapy or contraceptive pills,
antiestrogen drugs, or antidiabetic or insulin treatments
were also excluded.
The informed consent form was administered and
the objectives and benefits of the study were explained to
the subjects in the local language to get approval for their
participation. After an overnight fast, blood samples were
obtained by vein puncture under fully aseptic measures.
For premenopausal women, blood samples were collected
in the first week (early) of the follicular phase of the
menstrual cycle to lower inconsistency among subjects.
Serum was separated after clotting, centrifuged, and stored
at –30 °C. Serum leptin and estrogen were analyzed using
an ELISA kit manufactured by DIASource, Belgium. Intraand interassay CV for leptin was 13.3 and 10.2, respectively,
while its detection limit was 0.04 ng/mL.
The data were later entered and analyzed using
IBM SPSS 20 (9) statistical software and OpenEpi (v.3)
open source calculator (10). Student’s t-test was used to
compare mean values, while association between variables
was estimated by Pearson’s correlation. Significance of
difference between correlation coefficients was estimated
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via Fisher r-to-z transformation by using the online
statistical computation website VassarStats (11).
3. Results
This study encompasses 175 patients and 175 age-, sex-,
and BMI-matched healthy controls. To determine the
differences between patients and controls in both pre- and
postmenopausal women discretely, subjects were grouped
according to their menopausal status.
Comparisons of parameters were performed among
patients and controls grouped according to menopausal
status in the Table. There were 152 premenopausal subjects,
while there were 198 postmenopausal subjects. No
significant difference was observed for age or BMI between
the patients and controls in both groups independently,
while a significantly younger age at menarche was found
among the patients compared to the controls in both preand postmenopausal groups. Significantly higher mean
values were observed for serum leptin in the breast cancer
patients among both the pre- and postmenopausal groups.
Similarly, higher serum estrogen levels were found in both
groups, but the higher level attained statistical significance
in the postmenopausal group only.
Considering the subjects overall, no association
(r = 0.029) was found between serum estrogen and
serum leptin. However, after stratification according to
menopausal status, we found a weak positive association
(r = 0.186) among the premenopausal subjects that
attained statistical significance (P = 0.022) (Figure 1),
while a moderate positive association (r = 0.556) with high
statistical significance (P = 0.001) was found among the
postmenopausal subjects (Figure 2). Serum estrogen as
a dependent variable could be predicted based on serum
leptin levels among the postmenopausal subjects only,
with a moderate value of coefficient of determination
(R2 = 0.309). Furthermore, correlation coefficients (r) of
the pre- and postmenopausal groups were compared by
using Fisher r-to-z transformation and found to have a
statistically significant difference (z = 4.03, P = 0.0001).
4. Discussion
The rising incidence of breast cancer and related deaths
in the Asian population (12) has aroused public concern,
requiring more intense measures. Reiterating gene–
environment interaction, numerous studies have shown a
prevalence of metabolic dysregulation among breast cancer
cases. Elevated fasting blood glucose (13), elevated leptin
(14), and obesity (15) have been associated with increased
risk of breast cancer, particularly among postmenopausal
women. Adipose tissue supports carcinogenesis by
secreting growth factors and cytokines (16,17) that can
possibly be modulated as future preventive and therapeutic
measures.
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Table. Characteristics of pre- and postmenopausal breast cancer patients and healthy controls.
Premenopausal

Postmenopausal

No. Parameters

Patients n = 69
(mean ± SEM)

Controls n = 83
(mean ± SEM)

P-value

Patients n = 106
(mean ± SEM)

Controls n = 92
(mean ± SEM)

P-value

1

Age (years)

34.30 ± 0.49

34.62 ± 0.49

0.647

53.86 ± 0.47

53.45 ± 0.55

0.573

2

Abdominal
circumference (cm)

73.74 ± 1.91

75.88 ± 1.03

0.305

74.37 ± 1.18

75.06 ± 1.29

0.695

3

BMI (kg/m2)

22.36 ± 0.53

21.49 ± 0.39

0.185

21.12 ± 0.39

21.70 ± 0.41

0.313

4

Age at menarche
(years)

11.89 ± 0.24*

12.91 ± 0.17

0.001

11.92 ± 0.16**

12.93 ± 0.19

0.000

5

Age at menopausea

-

-

-

45.33 ± 0.59

43.84 ± 0.47

0.055

6

Serum estrogen (E2)
(pg/mL)

111.44 ± 6.81

106.58 ± 5.22

0.567

41.83 ± 1.59**

25.05 ± 1.90

0.001

7

Serum leptin
(ng/mL)

22.59 ± 1.17**

14.28 ± 1.157

0.001

25.73 ± 1.16*

20.74 ± 1.125

0.002

The Table shows the comparison of age, body mass index (BMI), serum estrogen, and serum leptin of cases with controls grouped
according to menopausal status into pre- and postmenopausal women. Significance of difference was determined by an independent
t-test between cases and controls. * P-value < 0.05 statistically significant.; ** P-value < 0.001 statistically significant.

This study demonstrates higher mean values of leptin
and estrogen among breast cancer patients in both the preand postmenopausal groups. This supports earlier studies
that showed an association of higher leptin levels (4,5,18)
and higher estrogen levels (19,20) with breast cancer.
However, various other studies have found no association
between elevated leptin and breast cancer risk (21,23).
Determination of association between leptin and
estrogen reveals dissimilar findings in the pre- and
postmenopausal groups. For the premenopausal group,
a weak positive correlation was found, while a moderate
positive association with high significance was found
for the postmenopausal group. A statistically significant
(P < 0.001) greater difference between correlation
coefficients was observed in the postmenopausal group.
This association may be explained by enhanced aromatase
activity via leptin converting androgens into estrogens,
particularly in the postmenopausal state, in the presence
of low estrogen production by the ovaries. The aromatase
enzyme that is expressed chiefly in the granulosa cells
of the ovaries for converting androgens into estrogens is
also expressed in adipose, liver, and other tissues (23). In
postmenopausal women, the primary site of aromatase
activity and estrogen biosynthesis shifts from the ovaries to

adipose tissue, and thus contributes to peripheral estrogen
biosynthesis, which has been suggested by a positive
correlation of estrogen with BMI after menopause (19).
Studies conducted by Magoffin et al. (24) and Kitawaki
et al. (25) have previously demonstrated that leptin
increases aromatase activity in adipose stromal cells and
granulosa cells, respectively. Other studies conducted by
Magglioni et al. (26) and Catalano et al. (27) showed that
leptin increased mRNA expression, content, and activity of
the aromatase enzyme in a breast cancer cell line. Hence,
leptin may act in an autocrine, paracrine, or endocrine
fashion, and exerts its mitogenic effect on mammary tissue
profoundly by increasing estradiol production.
However, this study has inherent limitations, including
those accompanying the cross-sectional nature of the
study design. The patients and controls were age-, sex-,
and BMI-matched; however, the study was not adjusted for
ethnicity and other risk factors. Similar future studies are
advocated that should be population-based, multicentric,
and prospective to determine any causal relationships.
In conclusion, the findings of this study suggest that
the proliferative effects of leptin on mammary tissue via
augmenting peripheral estrogen production are more
significant among postmenopausal subjects. Implicitly,
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Figure 1. Association of serum leptin with serum estradiol in premenopausal
subjects.

Figure 2. Association of serum leptin with serum estradiol in
postmenopausal subjects. Scatterplots illustrate the association of serum
leptin with serum estrogen. Distribution of data points for patients and
controls is represented by (▲) and (●), respectively. The strength of
association and relationship between parameters are described by the
linear trend line, values of correlation coefficient (r), and coefficient of
determination (R2).
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the therapeutic modulation of leptin may be advocated to
disrupt the leptin–aromatase–estrogen axis, particularly
among postmenopausal women. This proposition may
provide a target for potential adjuvant treatment of breast
cancer in patients with high levels of leptin along with high
estrogen concentrations.
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